Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
- Pasquini, Marcelo C.
- Zhang, Mei-Jie
- Medeiros, Bruno C.
- Armand, Philippe
- Hu, Zhen-Huan
- Nishihori, Taiga
- Aljurf, Mahmoud D.
- Akpek, Görgün
- Cahn, Jean-Yves
- Cairo, Mitchell S.
- Cerny, Jan
- Copelan, Edward A.
- Deol, Abhinav
- Freytes, César O.
- Gale, Robert Peter
- Ganguly, Siddhartha
- George, Biju
- Gupta, Vikas
- Hale, Gregory A.
- Kamble, Rammurti T.
- Klumpp, Thomas R.
- Lazarus, Hillard M.
- Luger, Selina M.
- Liesveld, Jane L.
- Litzow, Mark R.
- Marks, David I.
- Martino, Rodrigo
- Norkin, Maxim
- Olsson, Richard F.
- Oran, Betul
- Pawarode, Attaphol
- Pulsipher, Michael A.
- Ramanathan, Muthalagu
- Reshef, Ran
- Saad, Ayman A.
- Saber, Wael
- Savani, Bipin N.
- Schouten, Harry C.
- Ringdén, Olle
- Tallman, Martin S.
- Uy, Geoffrey L.
- Wood, William A.
- Wirk, Baldeep
- Pérez, Waleska S.
- Batiwalla, Minoo
- Weisdorf, Daniel J.
DOIAbstract
The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, N=240) and in myelodysplastic syndrome (MK+MDS, N=221) on hematopoietic cell transplantation (HCT) outcomes compared to other cytogenetically defined groups (AML, N=3,360; MDS, N=1,373) as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 1998 to 2011. MK+AML was associated with higher disease relapse (hazard ratio [HR] 1.98, p<0.01), similar transplant related mortality (TRM, HR 1.01, p=0.9) and worse survival (HR 1.67, p<0.01) compared to other cytogenetically defined AML. Among patients with MDS, MK+MDS was associated with higher disease rela...
Add to ORKG